Project Grant HT94252310375
Award Date
5/1/23
Completion Date
4/30/26
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Awardee
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. (UYLKBRENAPG5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Westlake, MD 20817, USA
Similar Awards
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
The Defense Health Agency awarded Thomas Jefferson University a $779,200 project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct senotherapy research for amyotrophic lateral sclerosis (ALS) from April 1, 2023 through March 31, 2025. The grant will support basic, applied, and advanced biomedical research investigating medical solutions for ALS, consistent with the program's goals of transforming military and public health care through innovative...
The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
The Johns Hopkins University was awarded a $1,623,356 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2026 to develop CHMP7 antisense oligonucleotide (ASO) therapy to repair nuclear pore and TDP43 dysfunction in sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The Military Medical Research and Development program supports basic, applied, and...
The University of Massachusetts Medical School was awarded a $1,005,000 Project Grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to develop pad inhibitors for the treatment of amyotrophic lateral sclerosis (ALS). The award, which commenced on September 30, 2024, will support research activities through September 29, 2026. The Medical School's Grants and Contracts Administration division, doing business as UMms, will lead the project...
The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...
The Department of Defense's Defense Health Agency awarded a $921,600 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) to research the "Therapeutic Effects of Sulfide Catabolism and Novel Trisulfide Compounds for Amyotrophic Lateral Sclerosis." The grant, under the Military Medical Research and Development program (CFDA 12.420), supports foundational biomedical research aimed at developing novel treatments for amyotrophic lateral sclerosis (ALS)....
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
The Department of the Army Medical Command, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,210,500 project grant to Mayo Clinic to explore novel biomarkers for amyotrophic lateral sclerosis (ALS) using a multiomics approach. The 3-year project (Apr 2025 - Mar 2028) will utilize immunoprofiling, extracellular vesicle analysis, and TDP-43 aggregation assays to identify potential diagnostic and prognostic markers for ALS. Mayo Clinic, a renowned non-profit...